How It Works
1/Our AI translates the patient's info into a computer-readable format
"...had progression on carbo/taxol/Keytruda..."
- Had treatment regimen of:
- Carboplatin (drug class: cytotoxic chemotherapy)
- Paclitaxel (drug class: cytotoxic chemotherapy)
- Pembrolizumab (drug class: PD-1/PD-L1 inhibitor)
- Result of regimen: progression
2/This data is used to get a list of matching trials
Trial inclusion criterion:
Progression on regimen containing chemotherapy and PD-1/PD-L1 inhibitor
- Regimen must contain:
- ≥1 drug in class: cytotoxic chemotherapy
- ≥1 drug in class: PD-1/PD-L1 inhibitor
- Result of regimen must have been: progression
3/Learn about the matching trials and find the ones that are the best fit
Tags in the trials list help you zero in on the best trials. Trials with better tags show up first.
In the AI Picks tab, chat with an AI agent that learns about matching trials and highlights promising ones.
Great — since you’re flexible, I pulled a broad set and focused first on trials most tailored to EGFR exon 20 insertion NSCLC after platinum chemotherapy. Below are the ones that look most promising for [Name]. I called out when a study has a close site (≤100 miles from the patient).
Our analysis helps identify the most promising drugs and trials:
Zongertinib clinical results
Zongertinib has shown promising preliminary results in ongoing clinical trials. In the Beamion LUNG-1 trial (NCT04886804), a Phase Ia/Ib first-in-human study, zongertinib demonstrated high response rates, particularly among NSCLC patients.
The drug was well tolerated, with low rates of EGFR-mediated adverse events and no discontinuations due to adverse events recorded during the Phase Ib trial. Initial efficacy data from Phase Ib reflected a high objective response rate (ORR) of 74% and a disease control rate (DCR) of 91% [1].
[1] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor, in patients with HER2-positive advanced NSCLC.
